相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
Nicola Ferri et al.
ATHEROSCLEROSIS (2012)
PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling
Kai Kysenius et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2012)
Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice
Maxime Denis et al.
CIRCULATION (2012)
Low-Density Lipoprotein Cholesterol-Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) Randomized Trial
Frederick Raal et al.
CIRCULATION (2012)
Antibodies to PCSK9 A Superior Way to Lower LDL Cholesterol?
Kara N. Maxwell et al.
CIRCULATION RESEARCH (2012)
Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial
Maartje E. Visser et al.
EUROPEAN HEART JOURNAL (2012)
An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes
Liwen Zhang et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2012)
Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients The GAUSS Randomized Trial
David Sullivan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9
Javier Chaparro-Riggers et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Loss- and Gain-of-function PCSK9 Variants CLEAVAGE SPECIFICITY, DOMINANT NEGATIVE EFFECTS, AND LOW DENSITY LIPOPROTEIN RECEPTOR (LDLR) DEGRADATION
Suzanne Benjannet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
The PCSK9 decade
Gilles Lambert et al.
JOURNAL OF LIPID RESEARCH (2012)
Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels Results From 2 Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1 Studies in Healthy Volunteers and Hypercholesterolemic Subjects on Statins
Clapton S. Dias et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
James M. McKenney et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway
Chun-Yan Wu et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2012)
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study
Michael J. Koren et al.
LANCET (2012)
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
Robert P. Giugliano et al.
LANCET (2012)
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
Evan A. Stein et al.
LANCET (2012)
PCSK9 LNA Antisense Oligonucleotides Induce Sustained Reduction of LDL Cholesterol in Nonhuman Primates
Marie W. Lindholm et al.
MOLECULAR THERAPY (2012)
Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
Evan A. Stein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
Eli M. Roth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Statin Therapy and the Risk of Intracerebral Hemorrhage A Meta-Analysis of 31 Randomized Controlled Trials
James S. McKinney et al.
STROKE (2012)
Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients
Dean G. Karalis et al.
CHOLESTEROL (2012)
Proprotein Convertase Substilisin/Kexin Type 9 Antagonism Reduces Low-Density Lipoprotein Cholesterol in Statin-Treated Hypercholesterolemic Nonhuman Primates
Hong Liang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue
Anna Roubtsova et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol A Randomized Controlled Trial
Stephen J. Nicholls et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Novel Domain Interaction Regulates Secretion of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein
Fen Du et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo
Yan G. Ni et al.
JOURNAL OF LIPID RESEARCH (2011)
Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg/dl With Rosuvastatin
Judith Hsia et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
William E. Boden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Adnectins: engineered target-binding protein therapeutics
D. Lipovsek
PROTEIN ENGINEERING DESIGN & SELECTION (2011)
Beyond LDL Cholesterol, a New Role for PCSK9
Omar N. Akram et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
The Influence of PCSK9 Polymorphisms on Serum Low-Density Lipoprotein Cholesterol and Risk of Atherosclerosis
Jean Davignon et al.
CURRENT ATHEROSCLEROSIS REPORTS (2010)
PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities
Majambu Mbikay et al.
FEBS LETTERS (2010)
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
Naveed Sattar et al.
LANCET (2010)
Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease.
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates
Ellen Marie Straarup et al.
NUCLEIC ACIDS RESEARCH (2010)
A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo
Nidhi Gupta et al.
PLOS ONE (2010)
Lipid levels-in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines
Amit Sachdeva et al.
AMERICAN HEART JOURNAL (2009)
Regulation of the proprotein convertase subtilisin/kexin type 9 in intestinal epithelial cells
Francois Leblond et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2009)
Proprotein Convertase Subtilisin Kexin Type 9 Null Mice Are Protected From Postprandial Triglyceridemia
Cedric Le May et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
The LDL Receptor
Joseph L. Goldstein et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
Increased Levels of 25 Hydroxyvitamin D and 1,25-Dihydroxyvitamin D After Rosuvastatin Treatment: A Novel Pleiotropic Effect of Statins?
Bunyamin Yavuz et al.
CARDIOVASCULAR DRUGS AND THERAPY (2009)
Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis
Swapnil N. Rajpathak et al.
DIABETES CARE (2009)
EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries
Kornelia Kotseva et al.
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION (2009)
PCSK9 Impedes Hepatitis C Virus Infection In Vitro and Modulates Liver CD81 Expression
Patrick Labonte et al.
HEPATOLOGY (2009)
Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells
Markey C. McNutt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
Joyce C. Y. Chan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes
Christopher P. Cannon et al.
AMERICAN HEART JOURNAL (2008)
PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide
LiXin Shan et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Proprotein convertase Subtilisin/Kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
Ahmed Zaid et al.
HEPATOLOGY (2008)
Genome-wide expression analysis of cells expressing gain of function mutant D374Y-PCSK9
Trine Ranheim et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2008)
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
Maria Frank-Kamenetsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study)
John C. LaRosa et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
Amanda J. Hooper et al.
ATHEROSCLEROSIS (2007)
Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells
Markey C. McNutt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice
Mark J. Graham et al.
JOURNAL OF LIPID RESEARCH (2007)
Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system
Steve Poirier et al.
JOURNAL OF NEUROCHEMISTRY (2006)
The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population
P Yue et al.
HUMAN MUTATION (2006)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote
Zhenze Zhao et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene - Long-term follow-up and treatment response
RP Naoumova et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy
SD Wiviott et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization
EC Charles et al.
AMERICAN JOURNAL OF MEDICINE (2005)
Intensive lipid lowering with atorvastatin in patients with stable coronary disease
JC LaRosa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
SM Grundy et al.
CIRCULATION (2004)
Optimal low-density lipoprotein is 50 to 70 mg/dl - Lower is better and physiologically normal
JH O'Keefe et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):: Liver regeneration and neuronal differentiation
NG Seidah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial
R Collins et al.
LANCET (2002)
分享论文
